Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, announced the completion of a $200 million Series B financing on August 2. As an important investor, LongRiver Investments supports the company’s pipeline progression and expansion for age-related degenerative diseases.
